Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

@article{Kosoglou2012PharmacokineticsAP,
  title={Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease},
  author={Teddy Kosoglou and Walter K Kraft and Bharath Rathna Kumar and Paul Statkevich and Fengjuan Xuan and Lei Ma and Lisa H K Jennings and James E. Schiller and Ronald B. Langdon and David L. Cutler},
  journal={European Journal of Clinical Pharmacology},
  year={2012},
  volume={68},
  pages={1049-1056}
}
To determine whether impaired renal function alters the pharmacokinetics (PK) of vorapaxar or its ability to inhibit thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. This was an open-label study in which 8 patients with end-stage renal disease (ESRD) on hemodialysis and 7 matched (based on age, gender, weight, and height) healthy… CONTINUE READING